224 related articles for article (PubMed ID: 30656389)
1. Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials.
Zhan T; Daniyal M; Li J; Mao Y
Herz; 2020 Dec; 45(Suppl 1):1-14. PubMed ID: 30656389
[TBL] [Abstract][Full Text] [Related]
2. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol.
Huang S; Zhao Q; Yang ZG; Diao KY; He Y; Shi K; Shen MT; Fu H; Guo YK
Heart Fail Rev; 2019 May; 24(3):325-333. PubMed ID: 30523513
[TBL] [Abstract][Full Text] [Related]
3. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
5. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials.
D'Amario D; Laborante R; Bianchini E; Galli M; Ciliberti G; Mennuni M; Patti G
Int J Cardiol; 2023 Nov; 391():131219. PubMed ID: 37527752
[TBL] [Abstract][Full Text] [Related]
6. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials.
Ma Y; Bai F; Qin F; Li J; Liu N; Li D; Li T; Xie H; Liu D; Zhou S; Liu Q
BMC Pharmacol Toxicol; 2019 Apr; 20(1):18. PubMed ID: 31023386
[TBL] [Abstract][Full Text] [Related]
7. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
Kheiri B; Abdalla A; Osman M; Haykal T; Chahine A; Ahmed S; Osman K; Hassan M; Bachuwa G; Bhatt DL
Am J Cardiol; 2018 Dec; 122(11):1959-1964. PubMed ID: 30292333
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
10. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Avila MS; Ayub-Ferreira SM; de Barros Wanderley MR; das Dores Cruz F; Gonçalves Brandão SM; Rigaud VOC; Higuchi-Dos-Santos MH; Hajjar LA; Kalil Filho R; Hoff PM; Sahade M; Ferrari MSM; de Paula Costa RL; Mano MS; Bittencourt Viana Cruz CB; Abduch MC; Lofrano Alves MS; Guimaraes GV; Issa VS; Bittencourt MS; Bocchi EA
J Am Coll Cardiol; 2018 May; 71(20):2281-2290. PubMed ID: 29540327
[TBL] [Abstract][Full Text] [Related]
11. Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis.
He D; Hu J; Li Y; Zeng X
Front Cardiovasc Med; 2022; 9():968534. PubMed ID: 36035937
[TBL] [Abstract][Full Text] [Related]
12. Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials.
Attar A; Behnagh AK; Hosseini M; Amanollahi F; Shafiekhani P; Kabir A
Cardiovasc Ther; 2022; 2022():8367444. PubMed ID: 36687509
[TBL] [Abstract][Full Text] [Related]
13. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.
Caspani F; Tralongo AC; Campiotti L; Asteggiano R; Guasti L; Squizzato A
Intern Emerg Med; 2021 Mar; 16(2):477-486. PubMed ID: 33011930
[TBL] [Abstract][Full Text] [Related]
14. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis.
Xu L; Long Y; Tang X; Zhang N
Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
17. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Lee M; Chung WB; Lee JE; Park CS; Park WC; Song BJ; Youn HJ
Cancer Med; 2021 Jun; 10(12):3964-3973. PubMed ID: 33998163
[TBL] [Abstract][Full Text] [Related]
18. Protective Effects of ACEI/ARB on Left Ventricular Function in Anthracycline-Induced Chronic Cardiotoxicity: A Meta-Analysis of Randomized Controlled Trials.
Lin H; Liang G; Wu Y; Chen L
Cardiology; 2021; 146(4):469-480. PubMed ID: 33946067
[TBL] [Abstract][Full Text] [Related]
19. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
Yun S; Vincelette ND; Abraham I
Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
